These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

968 related articles for article (PubMed ID: 12612647)

  • 21. PEGylation: an approach for drug delivery. A review.
    Jain A; Jain SK
    Crit Rev Ther Drug Carrier Syst; 2008; 25(5):403-47. PubMed ID: 19062633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-terminal site-specific PEGylation of a truncated thrombomodulin mutant with retention of full bioactivity.
    Cazalis CS; Haller CA; Sease-Cargo L; Chaikof EL
    Bioconjug Chem; 2004; 15(5):1005-9. PubMed ID: 15366953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
    Yang Z; Wang J; Lu Q; Xu J; Kobayashi Y; Takakura T; Takimoto A; Yoshioka T; Lian C; Chen C; Zhang D; Zhang Y; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Sep; 64(18):6673-8. PubMed ID: 15374983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging PEGylated drugs.
    Kang JS; Deluca PP; Lee KC
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):363-80. PubMed ID: 19453284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Site-specific PEGylation of proteins: recent developments.
    Nischan N; Hackenberger CP
    J Org Chem; 2014 Nov; 79(22):10727-33. PubMed ID: 25333794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-cancer PEG-enzymes: 30 years old, but still a current approach.
    Pasut G; Sergi M; Veronese FM
    Adv Drug Deliv Rev; 2008 Jan; 60(1):69-78. PubMed ID: 17869378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PEGylation of native disulfide bonds in proteins.
    Brocchini S; Balan S; Godwin A; Choi JW; Zloh M; Shaunak S
    Nat Protoc; 2006; 1(5):2241-52. PubMed ID: 17406463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential.
    Youn YS; Na DH; Yoo SD; Song SC; Lee KC
    Int J Biochem Cell Biol; 2005 Jul; 37(7):1525-33. PubMed ID: 15833282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration.
    Nojima Y; Suzuki Y; Iguchi K; Shiga T; Iwata A; Fujimoto T; Yoshida K; Shimizu H; Takeuchi T; Sato A
    Bioconjug Chem; 2008 Nov; 19(11):2253-9. PubMed ID: 18834167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Site-specific PEGylation of hemoglobin at Cys-93(beta): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain.
    Manjula BN; Tsai A; Upadhya R; Perumalsamy K; Smith PK; Malavalli A; Vandegriff K; Winslow RM; Intaglietta M; Prabhakaran M; Friedman JM; Acharya AS
    Bioconjug Chem; 2003; 14(2):464-72. PubMed ID: 12643758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.
    DeFrees S; Wang ZG; Xing R; Scott AE; Wang J; Zopf D; Gouty DL; Sjoberg ER; Panneerselvam K; Brinkman-Van der Linden EC; Bayer RJ; Tarp MA; Clausen H
    Glycobiology; 2006 Sep; 16(9):833-43. PubMed ID: 16717104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro refolding of PEGylated lipase.
    Kim MY; Kwon JS; Kim HJ; Lee EK
    J Biotechnol; 2007 Aug; 131(2):177-9. PubMed ID: 17683821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Problems and solutions in pegylation of protein and peptide drugs].
    Jiang ZY; Gao R; Wang YQ; Sun Y
    Yao Xue Xue Bao; 2002 May; 37(5):396-400. PubMed ID: 12579849
    [No Abstract]   [Full Text] [Related]  

  • 36. PEGylation of cyanovirin-N, an entry inhibitor of HIV.
    Zappe H; Snell ME; Bossard MJ
    Adv Drug Deliv Rev; 2008 Jan; 60(1):79-87. PubMed ID: 17884238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effects of preservatives in hydrogels].
    Hung C; Neumann S; Dittgen M
    Pharmazie; 1986 Aug; 41(8):601-2. PubMed ID: 3786389
    [No Abstract]   [Full Text] [Related]  

  • 38. Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable swelling, degradation, and release of pharmaceutically active proteins.
    van de Wetering P; Metters AT; Schoenmakers RG; Hubbell JA
    J Control Release; 2005 Feb; 102(3):619-27. PubMed ID: 15681084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
    Youn YS; Lee KC
    Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: a study with gentamicin.
    Marcus Y; Sasson K; Fridkin M; Shechter Y
    J Med Chem; 2008 Jul; 51(14):4300-5. PubMed ID: 18578475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.